681490-95-9 Usage
Description
(R)-2-chloro-1-[2-hydroxy-2-methyl-3-(4-nitrobenzoyloxy)]-propyl-4-nitroimidazole is a complex organic compound with a unique molecular structure. It is characterized by a chiral center, which gives it the (R)-configuration, and contains various functional groups such as a chloro, hydroxy, methyl, and nitrobenzoyloxy groups. (R)-2-chloro-1-[2-hydroxy-2-methyl-3-(4-nitrobenzoyloxy)]-propyl-4-nitroimidazole is a key intermediate in the synthesis of pharmaceuticals, particularly in the development of anti-tuberculosis drugs.
Uses
Used in Pharmaceutical Industry:
(R)-2-chloro-1-[2-hydroxy-2-methyl-3-(4-nitrobenzoyloxy)]-propyl-4-nitroimidazole is used as an intermediate in the synthesis of Delamanid (D230660), a novel anti-tuberculosis medication. Delamanid is designed to inhibit mycolic acid synthesis, which is essential for the growth and survival of Mycobacterium tuberculosis, the causative agent of tuberculosis. (R)-2-chloro-1-[2-hydroxy-2-methyl-3-(4-nitrobenzoyloxy)]-propyl-4-nitroimidazole has demonstrated potent in-vitro and in-vivo activity against drug-resistant strains of Mycobacterium tuberculosis, making it a valuable asset in the fight against this challenging disease.
Check Digit Verification of cas no
The CAS Registry Mumber 681490-95-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,1,4,9 and 0 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 681490-95:
(8*6)+(7*8)+(6*1)+(5*4)+(4*9)+(3*0)+(2*9)+(1*5)=189
189 % 10 = 9
So 681490-95-9 is a valid CAS Registry Number.
681490-95-9Relevant articles and documents
SUBSTITUTED 1,2,3-TRIAZOL-1-YL-METHYL-2,3-DIHYDRO-2-METHYL-6-NITROIMIDAZO[2,1-B]OXAZOLES AS ANTI-MYCOBACTERIAL AGENTS AND A PROCESS FOR THE PREPARATION THEREOF
-
Page/Page column 11; 13, (2016/05/24)
The present invention relates to new generation of triazole functionality containing 6-nitro-2,3-dihydroimidazooxazole agents for general formula I, their method of preparation and their use as drugs for treatment of tuberculosis, MDR-TB and XDR-TB either
Synthesis of new generation triazolyl- and isoxazolyl-containing 6-nitro-2,3-dihydroimidazooxazoles as anti-TB agents: In vitro, structure-activity relationship, pharmacokinetics and in vivo evaluation
Munagala, Gurunadham,Yempalla, Kushalava Reddy,Singh, Samsher,Sharma, Sumit,Kalia, Nitin Pal,Rajput, Vikrant Singh,Kumar, Sunil,Sawant, Sanghapal D.,Khan, Inshad Ali,Vishwakarma, Ram A.,Singh, Parvinder Pal
supporting information, p. 3610 - 3624 (2015/03/30)
The nitroimidazole scaffold has attracted great interest in the last decade, which ultimately led to the discovery of the successful drug Delamanid for multi-drug resistant tuberculosis (MDR-TB). Herein, we report medicinal chemistry on a 6-nitro-2,3-dihy
